Cargando…
Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw()
Medication-related osteonecrosis of jaws (MRONJ) is one of the most complicated inflammatory conditions in oral and maxillofacial region. It is very difficult to correctly evaluate the degree and extent of necrosis and infection. This refractory osteonecrosis often needs extended surgery, leading to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430078/ https://www.ncbi.nlm.nih.gov/pubmed/30949253 http://dx.doi.org/10.1016/j.jdsr.2018.12.001 |
_version_ | 1783405725652877312 |
---|---|
author | Kitagawa, Yoshimasa Ohga, Noritaka Asaka, Takuya Sato, Jun Hata, Hironobu Helman, Joseph Tsuboi, Kanako Amizuka, Norio Kuge, Yuji Shiga, Tohru |
author_facet | Kitagawa, Yoshimasa Ohga, Noritaka Asaka, Takuya Sato, Jun Hata, Hironobu Helman, Joseph Tsuboi, Kanako Amizuka, Norio Kuge, Yuji Shiga, Tohru |
author_sort | Kitagawa, Yoshimasa |
collection | PubMed |
description | Medication-related osteonecrosis of jaws (MRONJ) is one of the most complicated inflammatory conditions in oral and maxillofacial region. It is very difficult to correctly evaluate the degree and extent of necrosis and infection. This refractory osteonecrosis often needs extended surgery, leading to impaired quality-of-life. We have performed hyperbaric oxygen therapy (HBO) combined with conservative surgery for advanced cases. We have appraised the value of FDG-PET and 3-phase bone scintigraphy in the diagnosis and management of this condition. MRONJ showed significantly higher SUV(max) on FDG-PET than the others. Although the 3 phase pool bone images did not change significantly, perfusion and static bone image as well as PET showed remarkable response to HBO for MRONJ. SUV(max) after HBO was significantly lower than those of before HBO. These preliminary results indicate that FDG-PET is useful for monitoring the effect of HBO for MRONJ. |
format | Online Article Text |
id | pubmed-6430078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-64300782019-04-04 Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() Kitagawa, Yoshimasa Ohga, Noritaka Asaka, Takuya Sato, Jun Hata, Hironobu Helman, Joseph Tsuboi, Kanako Amizuka, Norio Kuge, Yuji Shiga, Tohru Jpn Dent Sci Rev Article Medication-related osteonecrosis of jaws (MRONJ) is one of the most complicated inflammatory conditions in oral and maxillofacial region. It is very difficult to correctly evaluate the degree and extent of necrosis and infection. This refractory osteonecrosis often needs extended surgery, leading to impaired quality-of-life. We have performed hyperbaric oxygen therapy (HBO) combined with conservative surgery for advanced cases. We have appraised the value of FDG-PET and 3-phase bone scintigraphy in the diagnosis and management of this condition. MRONJ showed significantly higher SUV(max) on FDG-PET than the others. Although the 3 phase pool bone images did not change significantly, perfusion and static bone image as well as PET showed remarkable response to HBO for MRONJ. SUV(max) after HBO was significantly lower than those of before HBO. These preliminary results indicate that FDG-PET is useful for monitoring the effect of HBO for MRONJ. Elsevier 2019-11 2019-03-15 /pmc/articles/PMC6430078/ /pubmed/30949253 http://dx.doi.org/10.1016/j.jdsr.2018.12.001 Text en © 2019 Published by Elsevier Ltd on behalf of The Japanese Association for Dental Science. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Kitagawa, Yoshimasa Ohga, Noritaka Asaka, Takuya Sato, Jun Hata, Hironobu Helman, Joseph Tsuboi, Kanako Amizuka, Norio Kuge, Yuji Shiga, Tohru Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title | Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title_full | Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title_fullStr | Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title_full_unstemmed | Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title_short | Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
title_sort | imaging modalities for drug-related osteonecrosis of the jaw (3), positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430078/ https://www.ncbi.nlm.nih.gov/pubmed/30949253 http://dx.doi.org/10.1016/j.jdsr.2018.12.001 |
work_keys_str_mv | AT kitagawayoshimasa imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT ohganoritaka imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT asakatakuya imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT satojun imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT hatahironobu imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT helmanjoseph imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT tsuboikanako imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT amizukanorio imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT kugeyuji imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw AT shigatohru imagingmodalitiesfordrugrelatedosteonecrosisofthejaw3positronemissiontomographyimagingforthediagnosisofmedicationrelatedosteonecrosisofthejaw |